HC Wainwright Reiterates Buy Rating for Hoth Therapeutics (NASDAQ:HOTH)

HC Wainwright reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report report published on Monday morning, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright also issued estimates for Hoth Therapeutics’ Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.86) EPS.

Hoth Therapeutics Stock Performance

NASDAQ HOTH opened at $1.07 on Monday. The stock has a market capitalization of $5.73 million, a price-to-earnings ratio of -0.47 and a beta of 0.80. The stock’s 50 day moving average price is $1.01 and its two-hundred day moving average price is $1.20. Hoth Therapeutics has a 52 week low of $0.72 and a 52 week high of $3.37.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). On average, equities research analysts forecast that Hoth Therapeutics will post -1.65 EPS for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.